A Three-year Follow-up of Intravitreal Triamcinolone Acetonide Injection and Macular Laser Photocoagulation for Diffuse Diabetic Macular Edema
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To report the three-year outcomes of macular laser photocoagulation following intravitreal injection of triamcinolone acetonide (IVTA) for diffuse diabetic macular edema (DME). Methods: A prospective, randomized controlled study was completed. Eighty-six eyes of 74 patients with diffuse DME were randomized into two groups. Eyes assigned to the combination group (n = 48) were subjected to macular laser photocoagulation three weeks after IVTA. Eyes in the IVTA group (n = 38) underwent IVTA alone. Central macular thickness was measured by optical coherence tomography, and the number of additional treatments and mean time to recurrence were assessed. Results: Thirty-seven eyes in the combination group and 26 eyes in the IVTA group completed the three-year follow-up. Recurrence of DME after initial treatment was not observed for nine of the 37 (24.3%) eyes in the combination group or for one of the 26 (3.9%) eyes in the IVTA group (p = 0.028). DME was absent for 19.9 months after treatment in the combination group compared to 10.3 months in the IVTA group (p = 0.027). The mean number of additional treatments was 0.92 in the combination group and 1.88 in the IVTA group (p = 0.001). Conclusions: Results in the subset of subjects who completed the three-year follow-up demonstrated that laser photocoagulation following IVTA is more effective than IVTA monotherapy for diffuse DME. Combination therapy required fewer additional treatments and resulted in a lower recurrence rate than IVTA monotherapy.
Abstract
Purpose: To report the three-year outcomes of macular laser photocoagulation following intravitreal injection of triamcinolone acetonide (IVTA) for diffuse diabetic macular edema (DME). Methods: A prospective, randomized controlled study was completed. Eighty-six eyes of 74 patients with diffuse DME were randomized into two groups. Eyes assigned to the combination group (n = 48) were subjected to macular laser photocoagulation three weeks after IVTA. Eyes in the IVTA group (n = 38) underwent IVTA alone. Central macular thickness was measured by optical coherence tomography, and the number of additional treatments and mean time to recurrence were assessed. Results: Thirty-seven eyes in the combination group and 26 eyes in the IVTA group completed the three-year follow-up. Recurrence of DME after initial treatment was not observed for nine of the 37 (24.3%) eyes in the combination group or for one of the 26 (3.9%) eyes in the IVTA group (p = 0.028). DME was absent for 19.9 months after treatment in the combination group compared to 10.3 months in the IVTA group (p = 0.027). The mean number of additional treatments was 0.92 in the combination group and 1.88 in the IVTA group (p = 0.001). Conclusions: Results in the subset of subjects who completed the three-year follow-up demonstrated that laser photocoagulation following IVTA is more effective than IVTA monotherapy for diffuse DME. Combination therapy required fewer additional treatments and resulted in a lower recurrence rate than IVTA monotherapy.
참고문헌 (19)
- "Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group", Arch Ophthalmol, 103, pp.1796~1806 (1985)
- Bresnick GH, "Diabetic maculopathy: a critical review highlighting diffuse macular edema", Ophthalmology, 90, pp.1301~1317 (1983)
- Lee CM, "Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results", Ophthalmology, 98, pp.1594~1602 (1991)
- Diabetic Retinopathy Clinical Research Network (DRCR.net), "Three-year follow-up of a randomized trial comparing focal", grid photocoagulation and intravitreal triamcinolone for diabetic macular edema, 2009, pp.127, 245~251
- Jonas JB, "Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema", Am J Ophthalmol, 138, pp.158~160 (2004)
- Jonas JB, "Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema", Am J Ophthalmol, 132, pp.425~427 (2001)
- Ciardella AP, "Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study", Br J Ophthalmol, 88, pp.1131~1136 (2004)
- Kang SW, "Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema", Arch Ophthalmol, 124, pp.653~658 (2006)
- Lam DS, "Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes", Ophthalmology, 114, pp.2162~2167 (2007)
- Diabetic Retinopathy Clinical Research Network, "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema", Ophthalmology, 117, pp.1064~1077 (2010)
- Gillies MC, "Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial", Ophthalmology, 118, pp.866~872 (2011)
- Kang SW, "Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema", Am J Ophthalmol, 144, pp.878~885 (2007)
- Estabrook EJ, "Can optical coherence tomography predict the outcome of laser photocoagulation for diabetic macular edema?", Ophthalmic Surg Lasers Imaging, 38, pp.478~483 (2007)
- Gillies MC, "Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial", Clin Experiment Ophthalmol, 38, pp.605~612 (2010)
- Arevalo JF, "Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months", Ophthalmology, 116, pp.1488~1497 (2009)
- Nagasawa T, "Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema", J Med Invest, 56, pp.111~115 (2009)
- Querques G, "Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection", Retina, 29, pp.1274~1281 (2009)
- Papadopoulou DN, "Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration", Ophthalmology, 116, pp.1755~1761 (2009)
- Von Hanno T, "Retinal artery occlusion following intravitreal anti-VEGF therapy", Acta Ophthalmol, 88, pp.263~266 (2010)